Skip to main content
Premium Trial:

Request an Annual Quote

Frances Heller

Frances Heller has joined Diagnostics For All's board, effective immediately. She currently is a trustee of the Dana-Farber Cancer Institute and a board member at Zafgen and Affinivax. Heller most recently was senior vice president of business development at Bristol-Myers Squibb and was a trustee of the Bristol-Myers Squibb Foundation. Before joining Bristol-Myers Squibb, she was executive vice president of business development at Exelixis Pharmaceuticals.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.